Pasithea Therapeutics will reveal new data on its macrocyclic MEK inhibitor, PAS-004, at the European Society for Medical Oncology (ESMO) Congress in 2026. The presentation promises insight into therapies targeting the MAPK pathway for advanced solid tumors.